DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 76 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Panacea Biotec Limited — Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company

NSE 1 hr ago·29 Sept 2026, 12:27 pm

Panacea Biotec

Panacea Biotec has informed stock exchanges that it is currently involved in pending litigation or disputes. The company has stated that the outcome of these legal matters could potentially have a material impact on its financial position and operations.

For investors, this news introduces an element of uncertainty. Legal disputes can lead to unexpected financial liabilities or operational disruptions, which may affect the company's profitability and share price in the short term.

Investors should keep a close watch on the company's future disclosures. Any updates regarding the resolution of these disputes or the specific nature of the legal challenges will be crucial for understanding the long-term implications for the business.